Tämä sivu käännettiin automaattisesti, eikä käännösten tarkkuutta voida taata. Katso englanninkielinen versio lähdetekstiä varten.

Kohdennettu lisälämpötilan hallinta akuutissa vakavassa häkämyrkytyksessä

sunnuntai 8. marraskuuta 2026 päivittänyt: Yong Sung Cha, Wonju Severance Christian Hospital

Kohdennettu lämpötilan hallinta yhdistettynä ylipainehappihoitoon akuutissa vakavassa hiilimonoksidimyrkytyksessä: monikeskusinen satunnaistettu kontrolloitu kliininen tutkimus (TTM-COHB-tutkimus)

This randomized trial will investigate important neurocognitive clinical outcomes of patients with acute severe carbon monoxide poisoning (ASCOP) randomized to receive either therapeutic hypothermia or normothermia combined with hyperbaric oxygen therapy (HBO).

Tutkimuksen yleiskatsaus

Yksityiskohtainen kuvaus

CO-poisoned patients are identified by medical history and carboxyhemoglobin (CO-Hb) value >5% (>10% in smokers). Patients presenting with acute CO poisoning will receive one HBO. ASCOP is defined as mental status showing response to painful stimulus or unresponsiveness requiring intubation for airway protection and ventilation support at the emerency department, and persistence of depressed mental status despite the HBO. After HBO treatment, eligible patients who provide consent will be randomly allocated to receive hypothermia, or normothermia treatment administered in a open label fashion except for blinding of outcome assessor.

Outcome measures will be administered at 1 month and 6 months after CO exposure. In addition, we will examine the differences in serum markers and mortality between the hypothermia and normothermia groups.

Opintotyyppi

Interventio

Ilmoittautuminen (Todellinen)

39

Vaihe

  • Ei sovellettavissa

Yhteystiedot ja paikat

Tässä osiossa on tutkimuksen suorittajien yhteystiedot ja tiedot siitä, missä tämä tutkimus suoritetaan.

Opiskelupaikat

    • Gangwon-do
      • Wŏnju, Gangwon-do, Etelä -Korea, 26426
        • Wonju Severance Christian Hospital
    • Incheon
      • Incheon, Incheon, Etelä -Korea, 22332
        • Inha University Hospital

Osallistumiskriteerit

Tutkijat etsivät ihmisiä, jotka sopivat tiettyyn kuvaukseen, jota kutsutaan kelpoisuuskriteereiksi. Joitakin esimerkkejä näistä kriteereistä ovat henkilön yleinen terveydentila tai aiemmat hoidot.

Kelpoisuusvaatimukset

Opintokelpoiset iät

19 vuotta ja vanhemmat (Aikuinen, Vanhempi Aikuinen)

Hyväksyy terveitä vapaaehtoisia

Ei

Sukupuolet, jotka voivat opiskella

Kaikki

Kuvaus

Inclusion Criteria:

  • ≥ 19 years.
  • Patients who received HBO within 24 hours for acute CO poisoning.
  • Patients who meet the definition of ASCOP (Patients incapable verbal obey after HBO).
  • Signed informed consent prior to study entry.

Exclusion Criteria:

  • Cardiac arrest before HBO
  • Previous neurocognitive disorders
  • Life-threatening underlying disease (ex: advanced cancer)
  • Evidence of co-ingestion of sedative or hypnotics confirmed by intravenous flumazenil administration or history taking at the emergency department
  • Absolute contraindication for TH (active severe bleeding and profound shock not controlled by vasoactive drugs)
  • No admission
  • The significant co-ingested drug levels, which are alter the consciousness, is confirmed from the drug analysis lab
  • Pregnancy
  • Burns
  • More than moderate burn or Inhalation burn
  • Burns complicated by other trauma
  • Electrical burn
  • Burns in high risk patients (Patients with chronic underlying diseases (i.e DM, ESRD, liver cirrhosis, etc) which may cause delays or aggravate the wound healing)

Opintosuunnitelma

Tässä osiossa on tietoja tutkimussuunnitelmasta, mukaan lukien kuinka tutkimus on suunniteltu ja mitä tutkimuksella mitataan.

Miten tutkimus on suunniteltu?

Suunnittelun yksityiskohdat

  • Ensisijainen käyttötarkoitus: Hoito
  • Jako: Satunnaistettu
  • Inventiomalli: Rinnakkaistehtävä
  • Naamiointi: Yksittäinen

Aseet ja interventiot

Osallistujaryhmä / Arm
Interventio / Hoito
Kokeellinen: Hypothermia group

Hypothermia group is then performed at a body temperature of 33±0.5 °C during 24 h using a surface cooling device as soon as possible after the HBO and research consent. After therapeutic hypothermia ended, rewarming is done slowly between 0.2℃ - 0.5℃/h for 12 hours. After rewarming, it will be held at 36.5 ℃ for 36 hours.

Targeted therapeutic hypothermia is then performed at a body temperature of 33±0.5 °C during 24 h using a surface cooling device as soon as possible after the HBO and research consent. After TH ended, rewarming is done slowly between 0.2℃ - 0.5℃/h for 12 hours. After rewarming, it will be held at 36.5 ℃ for 36 hours.

Active Comparator: Normothermia group

For normothermia group, it will be held at 36.5±0.5 ℃ for 72 hours using a surface cooling device after the HBO and research consent.

Targeted therapeutic normothermia will be held at 36.5±0.5 ℃ for 72 hours using a surface cooling device after the HBO and research consent.

Mitä tutkimuksessa mitataan?

Ensisijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Main neurocognitive outcome
Aikaikkuna: At 6 months after CO poisoning

Global Deterioration Scale [range 1 - 7 (worst score)]

At 6 months after CO poisoning

Toissijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Neurocognitive outcome
Aikaikkuna: At 1 month after CO poisoning

Global Deterioration Scale [range 1 - 7 (worst score)]

At 1 month after CO poisoning
Cerebral Performance Category
Aikaikkuna: At 1 month and 6 months after CO poisoning

Cerebral Performance Category [range 1 - 5 (worst score)]

At 1 month and 6 months after CO poisoning
modified Rankin scale
Aikaikkuna: At 1 month and 6 months after CO poisoning

modified Rankin scale [range 0 - 6 (worst score)]

At 1 month and 6 months after CO poisoning
Glasgow outcome scale
Aikaikkuna: At 1 month and 6 months after CO poisoning

Glasgow outcome scale [range 1 (worst score) - 5]

At 1 month and 6 months after CO poisoning
mini-mental status exam
Aikaikkuna: At 1 month and 6 months after CO poisoning

mini-mental status exam

At 1 month and 6 months after CO poisoning
Korean version of the Modified Barthel Index
Aikaikkuna: At 1 month and 6 months after CO poisoning

Korean version of the Modified Barthel Index

At 1 month and 6 months after CO poisoning
Mortality in intensive care unit
Aikaikkuna: Through study completion, an average of 6 months

Number of participants with mortality in intensive care unit

Through study completion, an average of 6 months
Mortality in intensive care unit
Aikaikkuna: Through study completion, an average of 6 months

Rate of participants with mortality in intensive care unit

Through study completion, an average of 6 months
In-hospital mortality
Aikaikkuna: Through study completion, an average of 6 months

Number of participants with in-hospital mortality

Through study completion, an average of 6 months
In-hospital mortality
Aikaikkuna: Through study completion, an average of 6 months

Rate of participants with in-hospital mortality

Through study completion, an average of 6 months
Mortality
Aikaikkuna: At 1, 3, and 6 months after CO poisoning

Number of participants with all cause mortality

At 1, 3, and 6 months after CO poisoning
Mortality
Aikaikkuna: At 1, 3, and 6 months after CO poisoning

Rate of participants with all cause mortality

At 1, 3, and 6 months after CO poisoning
Length of stay in intensive care unit and hospital
Aikaikkuna: Through study completion, an average of 6 months

Length of stay in intensive care unit and hospital

Through study completion, an average of 6 months
Pneumonia
Aikaikkuna: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)

Number of participants with the diagnosis of pneumonia. Diagnosis is established when the following two criteria are met: 1) the appearance of a new infiltrate or consolidation on chest x-ray; and 2) leukocytosis, or leukopenia, or the significant presence of meaningful bacteria in a sputum culture with the absence of other infections.

During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
Pneumonia
Aikaikkuna: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)

Rate of participants with the diagnosis of pneumonia. Diagnosis is established when the following two criteria are met: 1) the appearance of a new infiltrate or consolidation on chest x-ray; and 2) leukocytosis, or leukopenia, or the significant presence of meaningful bacteria in a sputum culture with the absence of other infections.

During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
Shock
Aikaikkuna: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)

Number of participants with shock. Diagnosis is diagnosed when a vasopressor is needed to resuscitate the patient and lactate levels exceeded 2.0 mmol/L.

During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
Shock
Aikaikkuna: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)

Rate of participants with shock. Diagnosis is diagnosed when a vasopressor is needed to resuscitate the patient and lactate levels exceeded 2.0 mmol/L.

During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
Bradycardia
Aikaikkuna: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)

Number of participants with dropped heart rate indicated drug or interventions

During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
Bradycardia
Aikaikkuna: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)

Rate of participants with dropped heart rate indicated drug or interventions

During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
Hypokalemia
Aikaikkuna: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)

Number of participants with serum K concentration <3.0 - 2.5 mmol/L

During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
Hypokalemia
Aikaikkuna: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)

Rate of participants with serum K concentration <3.0 - 2.5 mmol/L

During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
Hyperkalemia
Aikaikkuna: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)

Number of participants with serum K concentration >6.0 - 7.0 mmol/L

During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
Hyperkalemia
Aikaikkuna: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)

Rate of participants with serum K concentration >6.0 - 7.0 mmol/L

During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
Hyperglycemia
Aikaikkuna: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)

Number of participants with change (Insulin therapy initiated) in daily management from baseline for serum glucose

During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
Hyperglycemia
Aikaikkuna: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)

Rate of participants with change (Insulin therapy initiated) in daily management from baseline for serum glucose

During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
Hypophosphatemia
Aikaikkuna: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)

Number of participants with a disorder characterized by laboratory test results that indicate a low concentration of phosphates in the blood and indicated replacement therapy

During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
Hypophosphatemia
Aikaikkuna: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)

Rate of participants with a disorder characterized by laboratory test results that indicate a low concentration of phosphates in the blood and indicated replacement therapy

During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
Hypomagnesemia
Aikaikkuna: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)

Number of participants with serum magnesium <0.9 - 0.7 mg/dL

During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
Hypomagnesemia
Aikaikkuna: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)

Rate of participants with serum magnesium <0.9 - 0.7 mg/dL

During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
Prolonged prothrombin Time International Normalized Ratio
Aikaikkuna: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)

Number of participants with >2.5 x upper limit of the normal range and bleeding

During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
Prolonged prothrombin Time International Normalized Ratio
Aikaikkuna: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)

Rate of participants with >2.5 x upper limit of the normal range and bleeding

During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
Prolonged activated partial thromboplastin time
Aikaikkuna: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)

Number of participants with >2.5 x upper limit of the normal range and bleeding

During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
Prolonged activated partial thromboplastin time
Aikaikkuna: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)

Rate of participants with >2.5 x upper limit of the normal range and bleeding

During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
S100ß (serum)
Aikaikkuna: Within 14 days after CO exposure

Concentration of S100ß (serum)

Within 14 days after CO exposure
Neuronal specific enolase (serum)
Aikaikkuna: Within 14 days after CO exposure

Concentration of neuronal specific enolase (serum)

Within 14 days after CO exposure
Brain magnetic resonance image (MRI)
Aikaikkuna: Within 14 days after CO exposure

Number of participants with brain injury in brain MRI

Within 14 days after CO exposure
Brain magnetic resonance image (MRI)
Aikaikkuna: Within 14 days after CO exposure

Rate of participants with brain injury in brain MRI

Within 14 days after CO exposure

Yhteistyökumppanit ja tutkijat

Täältä löydät tähän tutkimukseen osallistuvat ihmiset ja organisaatiot.

Tutkijat

  • Päätutkija: Yong Sung Cha, MD, Wonju Severance Christian Hospital

Julkaisuja ja hyödyllisiä linkkejä

Tutkimusta koskevien tietojen syöttämisestä vastaava henkilö toimittaa nämä julkaisut vapaaehtoisesti. Nämä voivat koskea mitä tahansa tutkimukseen liittyvää.

Opintojen ennätyspäivät

Nämä päivämäärät seuraavat ClinicalTrials.gov-sivustolle lähetettyjen tutkimustietueiden ja yhteenvetojen edistymistä. National Library of Medicine (NLM) tarkistaa tutkimustiedot ja raportoidut tulokset varmistaakseen, että ne täyttävät tietyt laadunvalvontastandardit, ennen kuin ne julkaistaan ​​julkisella verkkosivustolla.

Opi tärkeimmät päivämäärät

Opiskelun aloitus (Todellinen)

Maanantai 25. lokakuuta 2021

Ensisijainen valmistuminen (Todellinen)

Perjantai 7. marraskuuta 2025

Opintojen valmistuminen (Todellinen)

Perjantai 7. marraskuuta 2025

Opintoihin ilmoittautumispäivät

Ensimmäinen lähetetty

Torstai 1. heinäkuuta 2021

Ensimmäinen toimitettu, joka täytti QC-kriteerit

Tiistai 13. heinäkuuta 2021

Ensimmäinen Lähetetty (Todellinen)

Maanantai 26. heinäkuuta 2021

Tutkimustietojen päivitykset

Viimeisin päivitys julkaistu (Todellinen)

Torstai 12. marraskuuta 2026

Viimeisin lähetetty päivitys, joka täytti QC-kriteerit

Sunnuntai 8. marraskuuta 2026

Viimeksi vahvistettu

Sunnuntai 1. kesäkuuta 2025

Lisää tietoa

Tähän tutkimukseen liittyvät termit

Muut tutkimustunnusnumerot

  • TTM-COHB trial
  • CR220011 (Muu tunniste: Wonju Severance Christian Hospital)
  • 2021-04-043 (Muu tunniste: Inha University Hospital)

Lääke- ja laitetiedot, tutkimusasiakirjat

Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta

Ei

Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta

Ei

Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .

Tilaa